An Introduction to Atherosclerosis
Atherosclerosis is defined as the build-up of plaque in the arteries, causing the narrowing of arteries and leading to the majority of heart attacks and strokes. Statin monotherapy has long been established as the gold-standard treatment, however the treatment landscape has grown over recent years with the introduction of new lipid-lowering therapies including fibrates, ezetimibe and PCSK-9 inhibitors. Further research and large-scale clinical trials are required to better compare their efficacy and safety with standard statin therapy.
Browse the content below where leading experts discuss the latest data in video interviews and short articles from our conference hub, and browse the selection of peer-reviewed articles from our journal portfolio. If you are looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Latest guidelines, novel therapies and emerging options for managing dyslipidemias and ASCVD risk in daily practice
Watch cardiology experts discuss how the latest guidelines and treatments are applied to reduce ASCVD risk in patients with dyslipidemias
- Choose appropriate lipid goals for patients with dyslipidemias and at risk of ASCVD, considering the latest guidelines
- Formulate guideline-based and forward-thinking strategies to reduce ASCVD risk in patients with dyslipidemias using appropriate lipid- and lipoprotein-lowering therapies
- Recognize special populations of patients with dyslipidemias and apply important considerations when treating them with lipid- and lipoprotein-lowering therapies
Multimodality Imaging Trials Evaluating the Impact of Omega-3 Fatty Acids on Coronary Artery Plaque Characteristics and Burden
Heart International. 2022;16(1):2–11 DOI: https://doi.org/10.17925/HI.2022.16.1.2
Despite improved treatment of atherosclerotic cardiovascular disease, coronary artery disease (CAD) remains the leading cause of death and disability worldwide.1 Treatment of traditional risk factors, mainly low-density lipoprotein (LDL) cholesterol, is the foundation of atherosclerotic risk reduction. However, a considerable residual risk for cardiovascular disease (CVD) still exists despite reducing LDL cholesterol.2 Beyond traditional risk factors, other […]
Signs You Could Be Suffering from Peripheral Artery Disease
Dr Jacob White is an interventional radiologist with over 15 years of experience. He currently serves as Medical Director at USA Vein Clinics, Vascular and Fibroid Centers and is on staff at the Jacobi Medical Centre in NYC. Dr White is a regular contributor to numerous medical journals. Despite being a common condition, […]
Brian Bergmark, ACC 2022: TRANSLATE-TIMI 70: Effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol
The TRANSLATE-TIMI 70 trial looks at the effect of vupanorsen on non-high-density lipoprotein cholesterol levels in statin-treated patients with elevated cholesterol. touchCARDIO spoke with Dr Brian Bergmark (Brigham and Women’s Hospital, Boston, MA) about the use of vupanorsen and the safety and efficacy of the TRANSLATE-TIMI 7 trial. Questions: What is vupanorsen and what is […]
Paul Ridker, ACC 2022: Secondary analysis of the CANTOS trial of the inflammatory hypothesis of atherothrombosis and chronic kidney disease
The CANTOS trial assessed the differential impact of residual inflammatory risk and residual cholesterol risk among atherosclerosis patients with and without chronic kidney disease. touchCARDIO spoke to Prof Paul Ridker (Harvard University, Boston, MA, USA) to discuss his presentation at the American College of Cardiology Annual Meeting 2022 entitled ‘Secondary Analysis of the CANTOS Trial: […]
Charalambos Antoniades, ESC 2021 – The Fat Attenuation Index
Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the fat attenuation index and its use in clinical decision making from the virtual ESC Congress 2021. Questions Can you tell us a little about the fat attenuation index (FAI) and how it can be […]
Charalambos Antoniades, ESC 2021 – High-sensitivity C-reactive Protein, Perivascular Adipose Tissue and Atherosclerosis
Prof. Charalambos Antoniades (Professor of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK) kindly shared his thoughts on the use of high-sensitivity C-reactive protein as a biomarker in clinical decision making, and the role of perivascular adipose tissue in the pathogenesis of atherosclerosis from the virtual ESC Congress 2021. Questions What is the […]
Stephen Nicholls, ESC 2021 – the HUYGENS Study
Prof. Stephen Nicholls (Professor of Cardiology, Monash University, Melbourne, Australia) kindly shared his thoughts on the impact of PCSK9 inhibitors on lipid-lowering therapy, the effects of statins on coronary atherosclerotic plaques and the HUYGENS study from the virtual ESC Congress 2021. Questions What has been the impact of PCSK9 inhibitors on lipid-lowering therapy, and what […]
What promise do novel lipoprotein-lowering therapies hold for effectively reducing ASCVD risk? Perspectives from a multidisciplinary team
Select a discussion in the hub to watch our multidisciplinary faculty share their insights on how novel lipoprotein-lowering therapies can help to reduce ASCVD risk and what this may mean for patient care in the future.
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!